GLP-1 side effects and results: separating hype from clinical data
Quick answer
The creator is in week one of semaglutide and reporting spontaneous caloric intake of approximately 888 calories per day, likely a consequence of GLP-1-mediated appetite suppression. This level of intake raises legitimate concerns about protein adequacy and lean mass preservation, particularly for someone aiming to lose approximately 25kg. Her self-directed plan to increase to 1,200 calories with a protein focus is clinically reasonable, though formal dietary support would be preferable to self-managed adjustments based on social media research.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @paulinalandina actually say?
On day 7 of semaglutide, the creator noticed her weight hadn't moved since day 4. Her working theory: eating too little, specifically around 888 calories a day, was stalling her progress. She plans to increase intake to roughly 1,200 calories and prioritise protein. She's right to flag this as a problem. Eating under 900 calories while on a GLP-1 receptor agonist is not a weight loss strategy, it's a fast track to muscle loss.
She describes a day that included a protein yogurt with raspberries, a thin bagel with butter and scrambled eggs, and a pre-prepared chicken and vegetable meal. That's not a terrible food lineup, but it's genuinely not enough food for a person with significant weight to lose who needs to preserve lean mass during the process.
Does the science back this up?
Yes, largely. Severe caloric restriction under GLP-1 suppression is a real and documented problem. The appetite suppression from semaglutide can push people well below adequate intake without them realising it, and the research is clear that this carries costs.
A 2021 analysis published in Obesity Reviews (Cava et al.) found that very low-calorie diets without adequate protein accelerate lean mass loss, which can slow metabolic rate and make long-term weight maintenance harder. Separately, the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed 14.9% average weight loss on semaglutide 2.4mg, but participants were counselled on 500-calorie deficits from a reasonable baseline, not near-starvation. The mechanism matters: GLP-1 drugs reduce appetite, not caloric requirements for tissue preservation.
Her instinct to increase protein is also supported. A 2022 paper in Nutrients (Carbone and Pasiakos) found that higher protein intake during caloric restriction, roughly 1.2-1.6g per kg of body weight, significantly reduces fat-free mass losses compared to standard protein intake.
What did they get wrong (or right)?
She got the diagnosis right but the framing slightly off. The plateau she noticed at day 4-7 is almost certainly not a metabolic adaptation to under-eating, that takes longer. Early plateaus on GLP-1s are typically water and glycogen fluctuations. A single week is genuinely not enough data to conclude anything meaningful about trajectory.
What she got right is the core problem: 888 calories is too low. And her instinct to increase protein is correct. Where the video wobbles is in suggesting this is a stall caused by metabolic slowdown from under-eating, when the more accurate framing is that inadequate protein intake risks body composition problems over weeks, not a halted scale in week one.
She's also honest about not being a nutritionist and asks for help directly in the video. That's a more responsible posture than most creators in this space take. Credit where it's due.
What should you actually know?
If you're on a GLP-1 receptor agonist and the drug is working as intended, you may not feel hungry enough to eat adequately. That is a feature of the medication, but it creates a real risk if you don't eat with intention rather than just appetite.
Clinically, 1,200 calories is generally considered the floor for supervised weight loss in women, and even that assumes a structured protein target. For someone with four stone to lose, eating at 888 calories likely means inadequate protein, inadequate micronutrient intake, and a higher proportion of lean mass lost relative to fat, which is the opposite of what you want for long-term outcomes.
The scale not moving in days 4-7 of week one is not a signal to panic. Weight loss on GLP-1 medications is not linear, and early fluctuations are dominated by fluid shifts. One week is not a stall. It's just one week.
- Eat enough protein: aim for at least 1.2g per kg of body weight daily
- Track food actively when appetite is suppressed, you may be under-eating without knowing it
- Do not interpret a 3-day plateau in week one as a metabolic failure
- Work with a registered dietitian if you can, not TikTok comment sections
- Weight loss on semaglutide typically accelerates over 12-16 weeks, not 7 days
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 side effects and results: separating hype from clinical data, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 side effects and results: separating hype from clinical data is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator is in week one of semaglutide and reporting spontaneous caloric intake of approximately 888 calories per day, likely a consequence of GLP-1-mediated appetite suppression.
FormBlends verdict
The creator is in week one of semaglutide and reporting spontaneous caloric intake of approximately 888 calories per day, likely a consequence of GLP-1-mediated appetite suppression. This level of intake raises legitimate concerns about protein adequacy and lean mass preservation, particularly for someone aiming to lose approximately 25kg. Her self-directed plan to increase to 1,200 calories with a protein focus is clinically reasonable, though formal dietary support would be preferable to self-managed adjustments based on social media research.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is in week one of semaglutide and reporting spontaneous caloric intake of approximately 888 calories per day, likely a consequence of GLP-1-mediated appetite suppression. This level of intake raises legitimate concerns about protein adequacy and lean mass preservation, particularly for someone aiming to lose approximately 25kg. Her self-directed plan to increase to 1,200 calories with a protein focus is clinically reasonable, though formal dietary support would be preferable to self-managed adjustments based on social media research.
- GLP-1 receptor agonists suppress appetite enough that some users fall below 900 calories per day without intending to, which risks lean mass loss over time (Cava et al., 2021, Obesity Reviews).
- The STEP 1 trial (Wilding et al., 2021, NEJM) used a structured 500-calorie deficit from a reasonable maintenance estimate, not sub-900 calorie intake, as the dietary component alongside semaglutide.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- GLP-1 receptor agonists suppress appetite enough that some users fall below 900 calories per day without intending to, which risks lean mass loss over time (Cava et al., 2021, Obesity Reviews).
- The STEP 1 trial (Wilding et al., 2021, NEJM) used a structured 500-calorie deficit from a reasonable maintenance estimate, not sub-900 calorie intake, as the dietary component alongside semaglutide.
- Protein targets of 1.2-1.6g per kg of body weight are supported by evidence for minimising muscle loss during caloric restriction (Carbone and Pasiakos, 2022, Nutrients).
- 1,200 calories is the widely accepted clinical minimum for women in supervised weight loss programmes, making her self-correction to this target broadly reasonable.
- A 3-day scale plateau in the first week of a GLP-1 medication is not a stall. It is normal weight fluctuation and cannot be meaningfully interpreted this early.
- Self-managing calorie targets based on TikTok research is less safe than working with a registered dietitian, particularly when appetite suppression is actively altering hunger cues.
- Week one of semaglutide is not representative of long-term outcomes. Meaningful weight loss trends on GLP-1 medications typically emerge over 12 to 16 weeks of consistent use.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
TheSourdoughStarter · TikTok creator
3.6K views on this video
GLP-1 side effects and results: separating hype from clinical data
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by TheSourdoughStarter, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.